<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817425</url>
  </required_header>
  <id_info>
    <org_study_id>2013078</org_study_id>
    <nct_id>NCT02817425</nct_id>
  </id_info>
  <brief_title>A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer</brief_title>
  <official_title>A Efficacy and Tolerability Study of Uracil/Ftorafur/Leucovorin Combined With Oxaliplatin (TEGAFOX) Sequential S-1 or SOX Sequential S-1 and S-1 Monotherapy in the Treatment of Adjuvant Chemotherapy for Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the three chemotherapy regimens(TEGAFOX Sequential S-1 or
      SOX Sequential S-1 or SOX non-Sequential S-1) for postoperative patients with gastric cancer,
      observe and record the efficacy and tolerance,to evaluate which regimen is better.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survial (OS)</measure>
    <time_frame>Event driven, an expected average of 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survial</measure>
    <time_frame>Event driven, an expected average of 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>Adverse events will be assessed at baseline (after the patients provided signed Informed Consent Form) until at least 4 weeks after the last dose of study drug was administered, an expected average of 3week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Event driven, an expected average of 48 months</time_frame>
    <description>Dose intensity will be used for present patients' compliance</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>SOX Sequential S-1 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received chemotherapy with&quot; oxaliplatin+ S-1 &quot; for 6 months and sequential &quot;S-1&quot; for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOX Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received chemotherapy with&quot; oxaliplatin+ S-1 &quot; for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEGAFOX Sequential S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received chemotherapy with&quot; TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium) &quot; for 6 months and sequential &quot;S-1&quot; for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOX Sequential S-1</intervention_name>
    <description>8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA &lt;1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA&gt;1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.</description>
    <arm_group_label>SOX Sequential S-1 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOX</intervention_name>
    <description>S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA &lt;1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA&gt;1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle</description>
    <arm_group_label>SOX Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEGAFOX Sequential S-1.</intervention_name>
    <description>6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA &lt;1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA&gt;1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.</description>
    <arm_group_label>TEGAFOX Sequential S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  75≧Age≧18

          -  Histologically or cytologically confirmed gastrointestinal cancer

          -  Stage Ⅱ or Ⅲ or Ⅳ

          -  ECOG ≦2

          -  Accept the gastric cancer radical resection

          -  Life expectancy of at least three months

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  History of severe hypersensitivity reactions to the ingredients of S-1\TF\5-FU/calcium
             folinate or oxaliplatin

          -  Inadequate hematopoietic function which is defined as below:

               -  white blood cell (WBC) less than 5x10^9/L

               -  absolute neutrophil count (ANC) less than 2x10^9/L

               -  platelets less than 100*10^9/L

          -  Inadequate hepatic or renal function which is defined as below:

               -  serum bilirubin greater than 2 times the upper limit of normal range

               -  alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than
                  2.5 times the ULN if no demonstrable liver metastases or greater than 5 times the
                  ULN in the presence of liver metastases

               -  blood creatinine level greater than 2 times ULN

          -  Presence of peripheral neuropathy

          -  Receiving a concomitant treatment with other fluoropyrimidine drug or flucytosine drug

          -  Women who is pregnant or lactating or fertile women of child-bearing potential unless
             using a reliable and appropriate contraceptive method throughout the treatment period
             (Including male)

          -  Psychiatric disorder or symptom that makes participation of the patient difficult;

          -  Concomitant illness that might be aggregated by active, non-controlled disease such as
             congestive heart failure, ischemic heart disease, uncontrolled hypertension or
             arrhythmia with in six months

          -  Severe complication(s), e.g., paresis of intestines, ileus, radiographically confirmed
             interstitial pneumonitis or pulmonary fibrosis, glomerulonephritis ,renal failure,
             poorly-controlled diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Hospital Affiliated to Lanzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Chen, MD</last_name>
    <phone>+86 0931-8942318</phone>
    <email>chenxiaomd@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Hospital Affiliated to Lanzhou University</name>
      <address>
        <city>LanZhou</city>
        <state>Gansu</state>
        <zip>0931</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>WEN QIU</last_name>
      <phone>0931-8487117</phone>
      <email>qiuwenmm@sina.com</email>
    </contact>
    <investigator>
      <last_name>XIAO CHEN, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>June 26, 2016</last_update_submitted>
  <last_update_submitted_qc>June 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Xiao Chen, MD</investigator_full_name>
    <investigator_title>Head of department</investigator_title>
  </responsible_party>
  <keyword>S-1</keyword>
  <keyword>Adjuvant Chemotherapy</keyword>
  <keyword>TEGAFOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

